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in the context of understanding fundamental hepatology, transla-
tional applications, and the challenges associated with the clinical 
qualification of novel DILI biomarkers.
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ImmuNologICal aSpeCTS of drug 
hyperSeNSITIVITy—from moleCule To maN
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Summary: Drug-induced liver injury (DILI) accounted for > 50% 
of cases of acute liver failure and 15% of patients undergoing liver 
transplantation between 1990 and 2002. One of the biggest fears is 
unpredictable idiosyncratic drug-induced liver injury (IDILI), which 
is a major contributor to the failure of a drug to process through 
development and is a major cause of withdrawal and black box warn-
ings. Due to the low concordance of the hepatotoxicity of drugs in 
animals and humans, a fundamental understanding of the mechanis-
tic basis from novel human-relevant in vitro models and biomarkers 
is critical for the development of effective strategies to prevent and 
predict DILI.
Hepatocellular activation of drugs has been widely implicated in 
immune-mediated DILI with concomitant activation of the adaptive 
immune system. Consistent with this hypothesis, a number of HLA 
alleles that are associated with DILI have been identified. Studies with 
patient PBMC and PBMC from drug-naive donors carrying HLA risk 
alleles have shown that drugs form specific associations with HLA 
risk alleles generating T-cell antigens and hence provide the immu-
nogenetic basis for the reaction. The identification of HLA alleles as 
predisposing factors for IDILI suggests that the adaptive immune sys-
tem also participates in reactions targeting the liver. Furthermore, the 
release of damage-associated molecular pattern molecules (DAMPs), 
such as high mobility group box-1, may serve to activate cells of 
the innate immune system. Certain mediators produced by innate 
immune cells may cause liver injury, but other factors are actually 
important to promote tissue repair and regeneration. However, to 
fully define cause and effect (bioactivation vs liver failure), an inte-
grated approach based on clinical studies, in vitro experiments, and 
animal models will be required, underpinned by appropriate bio-
analysis. We have been able to characterize covalent protein adducts 
in man formed by reactive drug metabolites (nevirapine, diclofenac) 
using techniques developed for β -lactam antibiotics that associate 
with various types of drug hypersensitivity. We have also developed 
in vitro models to look at the interplay between, genetic, chemical, 
and immunologic factors using cells from both hypersensitive and 
drug-naive individuals. Such techniques and concepts should enable 
us to elucidate various mechanistic pathways and thus define both 
chemical and biological variables that underpin this rare but serious 
form of DILI.
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NoVel ClINICal TrIal deSIgNS for aSSeSSINg 
The effICaCy of drugS
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Summary: There is a pressing need for faster and more efficient eval-
uation of new cancer agents to improve outcomes. Although many 
of the new targeted agents have proved disappointing, there is large 
range of new agents from varying classes that need to be evaluated 
alongside a need to evaluate biomarkers to identify more responsive 
patient subgroups effectively. The current evidence on biomarkers 
that predict the response to a therapy in oncology has often arisen 
from post hoc retrospective analyses of Phase III trial data. More 
recent trials are exploring novel ways to identify potential biomarkers 
of response much earlier in the drug development process, albeit in a 
more exploratory fashion. We suggest a new approach to trial design, 
which links novel treatment evaluation with the concurrent evalua-
tion of a biomarker within a confirmatory Phase II–III trial setting.
We describe such an approach used in a new protocol in advanced 
colorectal cancer called FOCUS4. The protocol will ultimately 
answer 3 research questions for a number of treatments and bio-
markers: (1) After a period of standard first-line chemotherapy, do 
targeted novel therapies provide strong signal of activity in differ-
ent biomarker-defined populations? (2) If so, do these definitively 
improve outcomes? (3) Is evidence of activity restricted only to the 
biomarker-defined groups?
Disclosure of Interest: None declared.
The fuTure of modelINg aNd SImulaTIoN 
approaCheS IN drug deVelopmeNT
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Summary: High development cost, low development success, cost-
disciplined health care policies, and intense competition demand an 
efficient drug development process. New compounds need to bring 
value to patients by being safe, efficacious, and cost-effective com-
pared with existing treatment options.
The goal of pharmacometrics/quantitative clinical pharmacology 
(also called Modeling and Simulation) is to optimize therapies for 
adult and pediatric patients through integration, innovation, and 
impact.1
-  Quantitatively integrate multisource data and clinical, biological, 
statistical, and mathematical concepts
-  Collaborate and innovate across disciplines, enhancing scientific 
understanding and knowledge
-  Impact and enhance key decisions in drug research and development
Pharmacometric approaches, including model-based meta-analy-
ses, allow for integration and utilization of biomarker, efficacy, and 
safety data and:
-  Provide a quantitative framework for comparative efficacy/safety 
assessments of drugs
-  Create opportunities to test assumptions through “virtual” experi-
ments and optimized clinical trials
-  Facilitate research and development of new therapies for adults 
and pediatrics
A sustained collaborative effort between academia, biotech/
pharma, hospitals and scientific societies involved in research, devel-
opment, and use of medicines is required to bring pharmacometrics/
quantitative clinical pharmacology to its full potential.
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C. Pichard*
Clinical Nutrition Geneva University Hospital, Geneva, 
Switzerland
Summary: Rationale: Chocolate is a popular food. Its consumption 
is largely associated with pleasure. Beliefs on its positive impact on 
health, physical, and mental strengths have been well established for 
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centuries. Recently, scientific and epidemiologic research has focused 
on its content in flavonoids and its potential to promote health and/or 
reduce risk factors for various diseases. Chocolate is also an energy-
rich food item. As such, it may promote positive energy balance, body 
weight gain, and ultimately become a risk for public health. Chemical 
compounds found in cocoa are fragile. During the multiple processes 
of chocolate production, these compounds may be degraded. In addi-
tion, adjunctions to cocoa to generate specific chocolate brands may 
have positive or negative biological of the final product. The art of the 
chocolate maker is to protect the cocoa values during the chocolate 
production and to select additives having interesting organoleptic 
values and positive health properties.
Conclusion: Many associations between chocolate consumption, 
health, and diseases are proven. The complexity of the cocoa com-
pounds warrants further investigations to substantiate the benefits/
disadvantages of chocolate, and to identify if chocolate should remain 
a food for pleasure and/or dietary supplement.
Learning objectives: Identify the chocolate’s properties. Learn the 
main hypotheses addressing the chocolate’s health-promoting values. 
Discover the relationship between chocolate, health, and diseases. 
Understand the differences between industrial and artisanal pro-
cesses, and their impact on the final product.
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elearNINg
V. Piguet*
Clinical Pharmacology and Toxicology, Geneva University 
Hospitals, Geneva, Switzerland
Summary: Medication adherence is poor, especially for chronic dis-
eases, leading to reduced treatment effectiveness and increased health 
care costs. As defined by WHO, “adherence is a multidimensional 
phenomenon determined by the interplay of five dimensions of which 
patient-related factors are just one determinant.” One of the differ-
ent ways to improve adherence is to enhance patients’ knowledge 
about medication that implies taking into account patients’ experi-
ences, expectations, and beliefs about medication efficacy and adverse 
effect in the context of their illness. Patient information leaflets (PIL), 
legally required by many countries, provide comprehensive informa-
tion, but they are not necessarily related to patients’ level of literacy 
nor do they answer individual situations. The Internet is more and 
more used as a source for health information. Patients report that 
this media allows them to get second opinions, cross-checking, and 
more tailored information through experience sharing. However, they 
could also be deceived, confused, or frightened by what they are 
finding on some Web sites or forums. ELearning programs based on 
constructivist learning theories are aiming, through self-involvement 
and interactivity, at improving patients’ knowledge and skills to use 
medicine in a safer way.
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The makINgS of The world-ClaSS aThleTe: 
phySIologIC, geNeTIC, pSyChoSoCIal aNd 
eCoNomIC deTermINaNTS
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Summary: A look at the final medal tally at the XXX Olympiad in 
London reveals that certain nations enjoy particular success on the 
running track and the marathon. Compelling examples are that of east 
African athletes from Kenya and Ethiopia, with their domination of 
middle- and long-distance running, and that of athletes from Jamaica 
and the United States, with their domination of sprint events. The 
London results have undoubtedly enhanced the concept that certain 
ethnic groups possess some inherent genetic advantage predisposing 
them to superior athletic performance. However, there is no genetic 
evidence to suggest that this is the case, although research is ongoing 
and predominantly implicates environmental factors. Genetic studies 
of elite distance runners from Kenya and Ethiopia and elite sprinters 
from Jamaica, the United States, and Nigeria do not find that these 
athletes possess a unique genetic makeup; rather they serve to high-
light the high degree of genetic diversity among ethnic groups. It is 
unjustified, therefore, to regard ethnic differences in sporting success 
as genetically mediated; to justify doing so one must identify the genes 
that are important, which until now has proven elusive.
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The bIopharmaCeuTICal INduSTry aNd  
The world aNTI-dopINg ageNCy
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Summary: Recent cases of doping in elite sports have shown that 
drugs in development have been misappropriated during clinical tri-
als and supplied to athletes or members of their entourage with a 
view to being used for performance-enhancing purposes. Certain 
innovative drugs, in particular those with chemical structures simi-
lar to endogenous substances, are especially difficult to detect. It 
requires substantial time and investment by antidoping authorities 
to develop detection methods that can then be integrated into the 
routine antidoping analysis of WADA-accredited laboratories. In a 
bid to facilitate detection methods for drugs in development that have 
doping potential, WADA has created partnerships and engaged in 
collaboration with pharmaceutical and biotechnology companies, as 
well as with the related biopharmaceutical associations. The ration-
ale is to bring about an exchange of information before these drugs 
have completed their clinical development and become commercially 
available. This exchange of information has already proven to be of 
great value to the antidoping authorities, while it has also allowed 
the pharmaceutical and biotechnology companies to benefit from 
WADA’s experience in the risk-management of their substances in 
development and the possibility of counterfeiting by illegal laborato-
ries and unscrupulous companies. This approach continues to expand 
as more companies embrace the collaborative model. The ultimate 
aim always will be to deter and prevent athletes from abusing these 
drugs, because such abuse poses a very real risk to their health and 
continues to be a major threat to clean athletes and clean sport.
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The role of The ClINICal pharmaCologIST 
IN pharmaCoeCoNomICS/healTh 
eCoNomICS
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Summary: Clinical pharmacologists should be playing a much larger 
role in the economic evaluation of medicines than hitherto. They have 
particular expertise in: choice of comparator interventions; appraisal 
of study designs of clinical effectiveness; appropriateness of post hoc 
subgroups; generalizability (external validity) of the pivotal studies; 
and inputs into, and face validity of, economic models.
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